1. Hematopoietic Stem Cell Transplantation in Patients with Lymphomatoid Granulomatosis: A European Group for Blood and Marrow Transplantation Report.
- Author
-
Siegloch, Kristina, Schmitz, Norbert, Wu, Huei-Shan, Friedrichs, Birte, van Imhoff, Gustaaf W., Montoto, Silvia, Holler, Ernst, Ribera, Josep Maria, Delage, Robert, Dührsen, Ulrich, Castillo, Nerea del, Harrison, Beth, Dreger, Peter, and Sureda, Anna
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *LYMPHOPROLIFERATIVE disorders , *AUTOTRANSPLANTATION , *BONE marrow transplantation , *GRAFT versus host disease , *FOLLOW-up studies (Medicine) - Abstract
Abstract: Lymphomatoid granulomatosis (LG) is a very rare, Epstein-Barr virus–associated lymphoproliferative disorder of B cells. Prognosis is poor, particularly after relapse and no curative treatment exists. We report the results of high-dose therapy and autologous stem cell transplantation (ASCT) or reduced-intensity conditioning and allogeneic stem cell transplantation (alloSCT) in patients with multiply relapsed LG. A European Group for Blood and Marrow Transplantation survey identified 10 patients who had received 9 ASCT and 4 alloSCT. All patients had active disease at the time of transplantation. With a median follow-up of 5.1 (range, 1.4 to 6.3) years, 6 patients are alive and disease-free. Two ASCT patients died of septicemia early after transplantation, and 1 committed suicide after being in continuous complete remission 19 months after ASCT. Another patient allografted 4 years after ASCT remained disease-free but died of severe graft-versus-host disease 3 months after alloSCT. High-dose therapy followed by ASCT and alloSCT are effective therapeutic options and should be considered in all patients with refractory and multiply relapsed LG. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF